Expansion of Psychiatric Turf

On September 21, the Guardian/Observer (UK) ran an online article by Vaughan Bell titled Changing brains: why neuroscience is ending the Prozac era. Thanks to Paul Mace on Twitter for the link. The gist of the article is that although the use of psycho-pharmaceutical products is at an all-time high and is still rising in most parts of the world, the psychiatric promise of drug-induced happiness may be at, or close to, its peak. ...

On January 17, 2013, Peter Kinderman, PhD, Professor of Clinical Psychology at the University of Liverpool, wrote an article titled Grief and Anxiety are not mental illnesses. On February 4, 2013, Steven Novella, MD, wrote a critique of Dr. Kinderman’s article. On February 20, I wrote a critique of Dr. Novella’s article. And finally, on September 17, Dr. Novella wrote More On Mental Illness Denial and How Not to Argue, a critique of my critique. ...

If you haven’t seen Jon Rappoport’s blog, please take a look. Here are two quotes from his September 22 post, Psychiatry targets college students for destruction: "The concept called 'mental disorder' is a sales pitch backed up by extraordinary PR, money, academic gibberish, and government-granted official status." "People need to wake up to the fact that the whole panoply of human suffering has been co-opted, taken over, redefined, re-translated into a lexicon of pseudoscience." ...

On September 12, Jeffry Lieberman, MD, President of the APA, posted an article on Psychiatric News titled IPS to Feature Patrick Kennedy, Celebrate Community Psychiatry. The article is a preview of an APA conference scheduled for October 10-13 in Philadelphia: “Transforming Psychiatric Practice, Reforming Health Care Delivery.” Dr. Lieberman tells us that he is very excited about the conference, and that the theme is particularly relevant "…given the changes we are experiencing in the profession and some of the exciting program events that I hope will support APA’s goal of being in the forefront of changes in the profession under health care reform." ...

Thanks to Graham Davey and Richard Pemberton on Twitter for the link to an interesting article in the August 29, 2013 issue of the Lancet. It’s titled Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010, and was written by Harvey A. Whiteford, et al. The Global Burden of Disease survey is a systematic, scientific attempt to quantify the comparative magnitude of disease, injuries, and risk factors by age, sex, and geography over time. ...

I’ve mentioned the CATIE study before. CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) was a NIMH-funded double blinded, randomized controlled trial comparing the effectiveness and side effects of newer-generation neuroleptics versus an older neuroleptic. CATIE-AD was a part of CATIE. The AD stands for Alzheimer’s disease. CATIE-AD was published in the New England Journal of Medicine in October 2006. The results of the study were as follows: "There were no significant differences among treatments with regard to the time to the discontinuation of treatment for any reason" ...

On Twitter yesterday, Robert Stamatakis commented: "I have to ask, I don't understand. Do you work in the UK? Your descriptions of psychiatry are nothing I recognize. These descriptions of psychiatry are nothing like the practice I see on a daily basis." I am certainly a very outspoken critic of psychiatry, and in that regard Robert's question/challenge is a fair one, to which I will try to respond. My primary criticism of modern psychiatry – and indeed the criticism that underpins all the others – is that its fundamental concepts are spurious. ...

BACKGROUND I’ve recently read Crazy Like Us: The Globalization of the American Psyche, by Ethan Watters (Free Press, 2010). It’s a great book, the theme of which is that western countries, especially America, are exporting the medicalization of human problems to less developed regions of the world. The new “illnesses” are being avidly promoted as if they had the same kind of reality as pneumonia or cancer, and are being foisted on vulnerable populations, with little regard for their impact on the cultures, ideas, sensitivities, and health of the recipients. ...

The FDA recently approved paroxetine (which in higher doses is marketed as the antidepressant Paxil) as a nonhormonal treatment for hot flashes in menopausal women. The drug will be marketed as Brisdelle. According to a New York Times article F.D.A. Approves a Drug for Hot Flashes, the approval was granted despite the fact that FDA’s own advisory committee voted 10 to 4 last March against approval. The reported reason for the negative vote was that in clinical trials, Brisdelle proved only minimally effective. ...

BACKGROUND As I suppose everyone knows by now, psychiatry has been on the receiving end of some very serious criticism in recent years. The criticism has come from many sources, including: survivors of psychiatric “treatment,” non-psychiatric mental health practitioners, journalists, the general public, and even from some psychiatrists themselves. The content of the criticisms has been equally varied, and includes: that the concept of mental illness is fundamentally spurious and devoid of explanatory significance; that psychiatric “treatment” (i.e. drugging people) is ineffective, physically damaging and disempowering; that psychiatry has forged and continues to maintain corrupt and corrupting relationships with the pharmaceutical industry with regards to the peddling of drugs and the hijacking of research for commercial ends; etc… ...